Junmin Zhang, Prof./Ph.D.

School of Pharmacy & State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, Gansu 730000, China

222 South Tianshui Road, Lanzhou, Gansu, China

Phone: 86 13669305351

E-mail: zhangjunmin@lzu.edu.cn

Professional Positions Held

Professor of Medicinal Chemistry & Chemical Biology, School of Pharmacy, State Key Laboratory of Applied Organic Chemistry, Lanzhou University.

Links:

https://orcid.org/0000-0001-5036-5559

https://www.webofscience.com/wos/author/record/AAI-5133-2020

https://www.scopus.com/authid/detail.uri?authorId=57022077600

https://www.researchgate.net/profile/Junmin-Zhang

https://scholar.google.com/citations?user=9-4xSuQAAAAJ&hl=zh-CN

https://pubmed.ncbi.nlm.nih.gov/?term=%28Junmin+Zhang%5BAuthor%5D%29+AND+%28Lanzhou+University%5BAffiliation%5D%29&sort=date

/col_js1/202212/C945D710770C2D0B6BFB099E0E348898.htm

Education and Training

2020. 01-2021. 12. 31: Postdoctoral, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau (SAR), China.

2014.09-2017.06: Ph.D. in Chemistry, State Key Laboratory of Applied Organic Chemistry, Lanzhou University. (Supervisor: Prof. Jianguo Fang).

2010.07-2014.09: Worked in School of Medicine, Northwest Minzu University.

2007.09-2010.06: MS in Medicine, School of Pharmacy, Lanzhou University.

2003.09-2007.06: BS in Medicine, School of Pharmacy, Lanzhou University.

Research

My research interests focus on the discovery of small molecules targeting cellular redox systems or protein kinases as potential therapeutic agents and the elucidation of their pharmacodynamics and pharmacokinetic mechanism.

Publications

* Corresponding author

[50]Cao Y, Zhou X, Nie Q, Zhang J*. Inhibition of the thioredoxin system for radiosensitization therapy of cancer. Eur J Med Chem, 2024, 268: 116218. (IF 6.7, SCI Q2)

[49]Lin X, Zhang J, Chu Y, Nie Q, Zhang J*. Berberine prevents NAFLD and HCC by modulating metabolic disorders. Pharmacol Ther, 2024, 254: 108593. (IF 13.5, SCI Q1)

[48]Li X, Zhang J, Liu G, Wu G, Wang R, Zhang J*. High altitude hypoxia and oxidative stress: The new hope brought by free radical scavengers. Life Sci, 2024, 336: 122319. (IF 6.1, SCI Q2)

[47]Tong H, Zhang J, Ma J, Zhang J*. Perspectives on 3D printed personalized medicines for pediatrics. Int J Pharm, 2024, 653: 123867. (IF 5.8, SCI Q2)

[46]Zhang J*, Leung EL. Natural Anticancer Molecules and Their Therapeutic Potential. Int J Mol Sci, 2023, 24. (IF 5.6, SCI Q2)

[45]Zhang J, Sun Y, He J, Wu G, Wang R, Zhang J*. Comprehensive Investigation of the Influence of High-Altitude Hypoxia on Clopidogrel Metabolism and Gut Microbiota. Curr Drug Metab, 2023, 24: 723-733. (IF 8.0, SCI Q1)

[44]Zhang J, Wang R, Pereira SA. Editorial: Drug metabolism and transport: the Frontier of personalized medicine. Front Pharmacol, 2023, 14: 1246827. (IF 2.3, SCI Q4)

[43]Chang B, Xu Q, Guo H, Zhong M, Shen R, Zhao L, Zhao J, Ma T, Chu Y, Zhang J*, Fang J*. Puromycin prodrug activation by thioredoxin reductase overcomes its promiscuous cytotoxicity, J Med Chem, 2023, 66, 3250-3261. (IF 8.0, SCI Q1)

[42]Zhang J, Liu P, Chen J, Yao D, Liu Q, Zhang J, Zhang HW, Leung EL, Yao XJ, Liu L. Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression, Pharmacol Res, 2023, 187, 106565. (IF 10.3, SCI Q1)

[41]Zhang J, Li X, Zhao Z, Cai W, Fang J. Thioredoxin signaling pathways in cancer, Antioxid Redox Signal, 2023, 38, 403-424. (IF 7.5, SCI Q2)

[40]Zhang J, Liu Y-Q, Fang J.The biological activities of quinolizidine alkaloids, Alkaloids Chem Biol, 2023, 89, 1-37. (Chapter)

[39]Zhang J, He J, Huang J, Li X, Fan X, Li W, Wu G, Xie C, Fan XX, Zhang J*, Yao X*, Wang R*, Leung EL*. Pharmacokinetics, absorption and transport mechanism for ginseng polysaccharides. Biomed Pharmacother, 2023, 162, 114610. (IF 7.4, SCI Q2)

[38]Peng S, Yu S, Zhang J*, Zhang J. 6-Shogaol as a novel thioredoxin reductase inhibitor induces oxidative-stress-mediated apoptosis in HeLa cells. Int J Mol Sci, 2023, 24, 4966. (IF 6.2, SCI Q2)

[37]Zhang J, Zhang J, Leung EL, Yao XJ. Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy. Expert Opin Investig Drugs, 2023, 32, 101-106. (IF 6.5, SCI Q2)

[36]Zhang J, Semlali A, Maycotte P, Saso L. Targeting redox regulation and autophagy systems for cancer therapy. Front Oncol, 2023, 13, 1146670. (IF 5.7, SCI Q3)

[35]Osama A, Zhang J, Fang J. Harnessing the ROS for cancer treatment. 2023, In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_255-1 (Chapter)

[34]Leung EL, Huang J, Zhang J(Co-first author), Zhang J, Wang M, Zhu Y, Meng Z, Yu H, Neher E, Ma L, Yao X. Novel anticancer strategy by targeting the gut microbial neurotransmitter signaling to overcome immunotherapy resistance. Antioxid Redox Signal, 2023, 38, 298-315. (IF 7.5, SCI Q2)

[33]Zhang J, Chen Y, Fang J. Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells. Free Radical Biol Med, 2022, 186, 99-109. (IF 8.4, SCI Q1)

[32]Zhang J, Zhang J, Liu Q, Fan X-X, Leung E L-H, Yao X, Liu L. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacol Therapeut, 2022, 229, 108050. (IF 13.4, SCI Q1)

[31]Zhang J*, Xu Q, Ma D. Inhibition of thioredoxin reductase by natural anticancer candidate β-lapachone accounts for triggering redox activation-mediated HL-60 cell apoptosis, Free Radical Biol Med, 2022, 180, 244-252. (IF 8.4, SCI Q1)

[30]Xu Q, Zhang J*, Zhao Z, Chu Y, Fang J. Revealing PACMA 31 as a new chemical type TrxR inhibitor to promote cancer cell apoptosis, Biochim Biophys Acta Mol Cell Res. 2022, 1869, 119323. (IF 5.0, SCI Q2)

[29]Xu Q, Zhang J*. Novel strategies for targeting the thioredoxin system for cancer therapy, Expert Opin Drug Discov, 2022, 17, 437-442. (IF 7.1, SCI Q2)

[28]Song Z, Zhang J (Co-first author), Xu Q, Shi D, Yao X, Fang J. Structural modification of aminophenylarsenoxides generates candidates for leukemia treatment via thioredoxin reductase inhibition. J Med Chem, 2021, 64, 16132-16146. (IF 7.4, SCI Q1)

[27]Zhang J, Zheng ZQ, Xu Q, Li Y, Gao K, Fang J. Onopordopicrin from the new genus Shangwua as a novel thioredoxin reductase inhibitor to induce oxidative stress-mediated tumor cell apoptosis, J Enzyme Inhib Med Chem, 2021, 36, 790-801. (IF 5.0, SCI Q2)

[26]Zhang J, Duan D, Song Z, Liu T, Hou Y, Fang J. Small molecules regulating reactive oxygen species homeostasis for cancer therapy, Med Res Rev, 2021, 41, 342-394. (IF 12.9, SCI Q1)

[25]Zhang, Duan D, Osama A, Fang J. Natural molecules targeting thioredoxin system and their therapeutic potential, Antioxid Redox Signal, 2021, 34, 1083-1107. (IF 8.4, SCI Q2)

[24]Zhang J., Morris-Natschke S L, Ma D, Shang XF, Yang C J, Liu YQ, Lee KH. Biologically active indolizidine alkaloids, Med Res Rev, 2021, 41, 928-960. (IF 12.9, SCI Q1)

[23]Zhang J, Zhang B, Li X, Han X, Liu R, Fang J*. Small molecule inhibitors of mammalian thioredoxin reductase as potential anticancer agents: An update. Med Res Rev, 2019, 39, 5-39. (IF 8.7, SCI Q1)

[22]Zhang J, Duan D, Xu J, Fang J*. Redox-dependent copper carrier promotes cellular copper uptake and oxidative stress-mediated apoptosis of cancer cells. ACS Appl. Mater. Interfaces, 2018, 10, 33010-33021. (IF 8.1, SCI Q1)

[21]Zhang J, Li X., Han X., Liu R., Fang J., Targeting the thioredoxin system for cancer therapy. Trends Pharmacol Sci, 2017, 38, 794-808. (IF 12.1, SCI Q1)

[20]Zhang J, Liu Y, Shi D, Hu G, Zhang B, Li X, Liu R, Han X, Yao X, Fang J*. Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent. Eur J Med Chem, 2017, 140, 435-447. (IF 4.5, SCI Q2)

[19]Zhang J, Yao J, Peng S, Li X, Fang J*. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase. Biochim Biophys Acta, 2017, 1863, 129-138. (IF 5.5, SCI Q2)

[18]Zhang J, Li Y, Duan D, Yao J, Gao K, Fang J*. Inhibition of thioredoxin reductase by alantolactone prompts oxidative stress-mediated apoptosis of HeLa cells. Biochem Pharmacol, 2016, 102, 34-44. (IF 5.1, SCI Q2)

[17]Zhang J, Peng S, Li X, Liu R, Han X, Fang J*. Targeting thioredoxin reductase by plumbagin contributes to inducing apoptosis of HL-60 cells. Arch Bioche Biophys, 2017, 619, 16-26. (IF 4.1, SCI Q3)

[16]Zhang J, Xu Q, Yang H Y, Yang M, Fang J. Gao K. Inhibition of thioredoxin reductase by santamarine conferring anticancer effect in HeLa cells, Front Mol Biosci, 2021, 8, 806. (IF 6.1, SCI Q2)

[15]Wei X, Zhong M, Wang S, Li L, Song Z, Zhang J*, Xu J, Fang J*. Synthesis and biological evaluation of disulfides as anticancer agents with thioredoxin inhibition, Bioorg Chem, 2021, 110, 104814. (IF 5.3, SCI Q2)

[14]Zhang J, Zhang M, Zhang J*, Wang R*. Enhanced P-glycoprotein expression under high-altitude hypoxia contributes to increased phenytoin levels and reduced clearance in rats, Eur J Pharm Sci, 2020,153, 105490. (IF 4.4, SCI Q2)

[13]Liu T, Zhang J*, Han X, Xu J, Wu Y, Fang J*. Promotion of Hela cells apoptosis by cynaropicrin involving inhibition of thioredoxin reductase and induction of oxidative stress. Free Radic Biol Med, 2019, 135, 216-226. (IF 5.7, SCI Q2)

[12]Zhang J, Zhang J*, Wang R*, Jia Z, Effects of gut microbiota on drug metabolism and guidance for rational drug use under hypoxic conditions at high altitudes. Curr Drug Metab, 2019, 20, 155-165. (IF 3.7, SCI Q3)

[11]Han X, Zhang J*, Shi D, Wu Y, Liu R, Liu T, Xu J, Yao X, Fang J*. Targeting thioredoxin reductase by ibrutinib promotes apoptosis of SMMC-7721 cells. J Pharmacol Exp Ther, 2019, 369, 212-222. (IF 4.0, SCI Q2)

[10]Bioassay-guided isolation of dehydrocostus lactone from Saussurea lappa: A new targeted cytosolic thioredoxin reductase anticancer agent. Arch Biochem Biophys 2016, 607: 20-26. (IF 4.1, SCI Q3)

[9]Shi X, Liu D, Zhang J, Hu P, Shen W, Fan B, Ma Q, Wang X. Extraction and purification of total flavonoids from pine needles of Cedrus deodara contribute to anti-tumor in vitro. BMC Complement Altern Med, 2016, 16: 245. (IF 2.3, SCI Q2)

[8]Shi XF, Ma QH, Yao ZY, Zhang J, Liu DY, Shen W, Fan B, Wang XD. Further iridoids from the roots of Patrinia scabra. Phytochem Lett 2015, 13: 152-155. (IF 1.7, SCI Q4)

[7]Zhang J, Chen Y, Sun Y, Wang R, Zhang J*, Jia Z. Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine. Drug Deliv, 2018, 25: 1175-1181. (IF 6.0, SCI Q2)

[6]Duan D, Zhang J, Yao J, Liu Y, Fang J. Targeting thioredoxin reductase by parthenolide contributes to inducing apoptosis of HeLa cells. J Biol Chem, 2016, 291, 10021-10031. (IF 4.2, SCI Q2)

[5]Ma H, Zhang J, Zhang Z, Liu Y, Fang J. A fast response and red emission probe for mammalian thioredoxin reductase. Chem Commun, 2016, 52, 12060-12063. (IF 6.3, SCI Q2)

[4]Zhang B, Zhang J, Peng S, Liu, R, Li X, Hou Y, Han X, Fang J. Thioredoxin reductase inhibitors: a patent review. Expert Opin Ther Pat, 2017, 27, 547-556. (IF 3.7, SCI Q2)

[3]Zheng ZQ, Wei WJ, Zhang J, Li HY, Xu K, Xu J, Tang B, Li Y, Gao K. Heliaquanoids A-E, Five Sesquiterpenoid Dimers from Inula helianthus-aquatica. J Org Chem, 2019, 84, 4473-4477. (IF 4.3, SCI Q2)

[2]Jiang CX, Li J, Zhang J, Jin XJ, Yu B, Fang J, Wu QX. Isolation, identification, and activity evaluation of chemical constituents from Soil Fungus Fusarium avenaceum SF-1502 and endophytic fungus Fusarium Proliferatum AF-04. J Agric Food Chem, 2019, 67, 1839-1846. (IF 5.3, SCI Q1)

[1]Liu R, Shi D, Zhang J, Li X, Han X, Yao X, Fang J. Xanthatin promotes apoptosis via inhibiting thioredoxin reductase and eliciting oxidative stress. Mol Pharm, 2018, 15, 3285-3296. (IF 4.3, SCI Q2)

Research Funding

Principal Investigator (PI)

2020,National Natural Science Foundation of China (82003779).

2019,International Postdoctoral Exchange Fellowship Program (Macao Young Scholars Program).

2019,Lanzhou University (the Fundamental Research Funds for the Central Universities,lzujbky-2020-47).

2018,Natural Science Foundation of Gansu Province (18JR3RA296).

2018,Lanzhou University (the Fundamental Research Funds for the Central Universities,lzujbky-2018-39).

Co-PI

National Natural Science Foundation of China (21572093, 31670767, 21778028).

Honor and Awards

2019,won the Advanced Individual in the Work of "Entering into Student Life, Entering into Student Learning, Entering into Student's Mind" at Lanzhou University.

2019,won the First Prize of the Young Teachers Lecture Competition for the School of Pharmacy.

2018,won the Third Prize of the Medical College Young Teachers Teaching Skills Competition.

2017,won the Second Prize of the Young Teachers Lecture Competition for the School of Pharmacy.

2015,won the National Scholarship for Postgraduate students

2012,won the Second Prize of the Gansu Scientific and Technological Progress Awards.

2012,won the Gansu Huangpumi's Second Prize for Chinese Medicine Technology.

Memberships in panels, boards, etc., and individual scientific reviewing activities

•Associate Editor: Frontiers in Pharmacology, Journal of Cellular and Molecular Medicine, Frontiers in Oncology, Frontiers in Chemistry, Drug Design, Development and Therapy, Chinese Journal of Modern Applied Pharmacy (2020- to date).

•Editorial Board: Oxidative Medicine and Cellular Longevity (Academic Editor), International Journal of Molecular Sciences (Topical Advisory Panel Member), Current Drug Delivery, Acta Materia Medica, Antioxidants (Reviewer Board), Chinese Medicine

•Member of the Chinese Pharmacological Society, Chinese Chemical Society, China.

•Director of the Chinese Medicine Immunology Committee of the World Federation of Chinese Medicine Societies (B06222014931, 2022.01.24-2023.12.30)

Reviewer for the following Journals: Trends in Pharmacological Sciences, Redox Biology, ACS Medicinal Chemistry Letters, Pharmacological Research, Journal of Natural Products, Phytomedicine, Journal of Ethnopharmacology, Frontiers in Immunology, Expert Opinion on Therapeutic Patents, Antioxidants, Cancers, Frontiers in Chemistry, Frontiers in Oncology, Frontiers in Pharmacology, Journal of Cellular and Molecular Medicine, International Journal of Molecular Sciences, Frontiers in Cellular and Infection, Combinatorial Chemistry & High Throughput Screening, Molecules, Current Pharmaceutical Biotechnology, Drug Design, Development and Therapy, OncoTargets and Therapy, et al.